Results 271 to 280 of about 1,362,647 (365)

Exploring Patient Mealtime Experience in an Acute Care Setting Using the Modified Austin Health Patient Mealtime Experience Tool. [PDF]

J Hum Nutr Diet
Lam L, Ussher H, Trakman G, Daglas A, Hamilton E, Ballantyne L, Fox V, Furness K.   +7 more
europepmc   +1 more source

Evaluation of exposure‐response‐safety relationship of model‐informed low‐dose 500 mg abiraterone acetate in prostate cancer patients

Cancer Communications, EarlyView.
Edmund Chiong, Ziteng Wang, Eleanor Jing Yi Cheong, Yi Chen Yao, Sin Mun Tham, Revathi Periaswami, Poh Choo Toh, Ziting Wang, Qing Hui Wu, Woon Chau Tsang, Arshvin Kesavan, Alvin Seng Cheong Wong, Patrick Thomas Wong, Felicia Lim, Shuaibing Liu, Eric Chun Yong Chan   +15 more
wiley   +1 more source

Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Cytochrome P450 (CYP) 3A plays a significant role in fruquintinib metabolism in vitro. This 2‐part, 2‐period fixed‐sequence study investigated the impact of CYP3A inhibition (itraconazole) and CYP3A induction (rifampin) on the pharmacokinetics (PK) of fruquintinib and M11, its main metabolite.
Martha Gonzalez, Zhao Yang, William R Schelman, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +5 more
wiley   +1 more source

The Effect of an Ordinary Meal on the Electrocardiogram. Normal Standards in Middle-Aged Men and Women [PDF]

, 1950
Ernst Simonson, Ancel Keys
openalex   +1 more source

Occupational therapy and registered dietitian services to reduce fall risk among home delivered meal clients: a randomized controlled feasibility trial. [PDF]

BMC Geriatr
Juckett LA, Joshi S, Hyer JM, Hariharan G, Thomas KS, Sathya TS, Howard ML, Bunck LE, Rowe ML, Devier A, Parrett K, LifeCare Alliance SixtyPLUS Team.   +11 more
europepmc   +1 more source

First‐in‐Human Phase 1 Study to Evaluate the Clinical Pharmacology Properties of RBN‐3143, a Novel Inhibitor of Mono‐Adenosine Diphosphate Ribosyltransferase‐PARP14

Clinical Pharmacology in Drug Development, EarlyView.
Abstract RBN‐3143 is an inhibitor of PARP14 in development for inflammatory diseases. Multiple assessments were conducted to evaluate the clinical pharmacology properties of RBN‐3134. A randomized, double‐blind, placebo‐controlled study assigned healthy volunteers (HVs) to single ascending doses (SADs) (25‐1000 mg) or multiple ascending doses (MADs ...
Thomas M. Polasek, Alexandra Cole, Viviana Bozón, Erika Manyak, Jonathan Novak, Barbara Yang, Briohny A. Johnston, Sudha Parasuraman, Kushal J. Paneliya, Virna Schuck   +9 more
wiley   +1 more source

Cottonseed Meal as a Substitute for Soybean Oil Meal in Poultry Rations ,

, 1955
John W. West
openalex   +1 more source

Daily Eating Window and Obesity Markers in a Sample of Schoolchildren from Vienna: Insights from the EDDY Study. [PDF]

Nutrients
Moliterno P, Donhauser V, Widhalm K.
europepmc   +1 more source

Effect of Cytochrome P450 3A Inhibition and Induction by Itraconazole and Rifampin on Tazemetostat Pharmacokinetics in Patients With Advanced Malignancies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This study (NCT04537715) investigated itraconazole (strong cytochrome P450 [CYP] 3A inhibitor) and rifampin (strong CYP3A inducer) on tazemetostat pharmacokinetics. In Part 1, patients received tazemetostat 400 mg orally on Days 1, 15, and 36, and 400 mg twice daily on Days 3‐14 and Days 21‐35.
Yingxue Chen, Renli Teng, Attila Szanto, Apoorva Kapopara, Rajat Bannerji, Julien Ogier, Devalingam Mahalingam   +6 more
wiley   +1 more source

Deep mining in the dorsal raphe: cholecystokinin-expressing neurons encode satiation-related cues to regulate meal size. [PDF]

Signal Transduct Target Ther
Röhrdanz N, Wulff P, Balueva K.
europepmc   +1 more source